To state the obvious: early use of Zy... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

To state the obvious: early use of Zytiga or Xtandi extends survival in APC

Tall_Allen profile image
58 Replies

I was chagrinned to read a post here the other day by a patient advocating less use of advanced hormonal therapies. He cited Rahul Aggarwal's study of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC). Since I know and respect Dr. Aggarwal, I reached out to him and told him what that ill-informed patient was advocating. Here's what he replied:

"Although long term androgen deprivation therapy may be associated with the development of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in a minority of patients, multiple studies have confirmed the long-term benefit of abiraterone and enzalutamide for prostate cancer patients in various disease settings. Use of these agents should not be limited by concern for the subsequent development of t-SCNC.”

• His study does not prove that those meds cause t-SCNC, but only shows an association in heavily pre-treated men with mCRPC. This is an important distinction. (It's like observing that many men with high PSA have prostate cancer (an association) and erroneously concluding that high PSA causes prostate cancer.)

• t-SCNC may simply be part of the natural course of advanced PC, and may occur whatever treatments are used. The hormone therapies may only be selecting for the resistant cancer that survives their use. The resistant cancer may always have been there.

• Zytiga and Xtandi have been proven to add years of life in the mHSPC setting in some men, and months in the mCRPC setting, so avoiding those medicines will reduce expected survival.

• A recent study at Johns Hopkins showed that the t-SCNC subtype is less virulent than de novo SCNC onlinelibrary.wiley.com/doi...

Remember, stuff on this forum (from me or anyone else) is not medical advice. Many patients post research that they do not really understand, and often misinterpret. They may be good topics for discussion with one's oncologist, but they should never be taken as sufficient reason to alter therapies. There is a lot of good information shared here too. I wish that I had more time to critique all the misinformation on this site, but there aren't enough hours in the day - I only manage to read what lands in my inbox and ignore much of the low-level research posted on this site.

Written by
Tall_Allen profile image
Tall_Allen
To view profiles and participate in discussions please or .
Read more about...
58 Replies
SPEEDYX profile image
SPEEDYX

With progress there are always shared risk!!!...We pray for the best outcome.

Ahk1 profile image
Ahk1

Very good points, TA. Thanks for posting them.

cesanon profile image
cesanon

Tall_Allen

Thanks for doing such a good job of keeping this community so very very very well informed.

Your informational vigilance is likely saving lives, or at least materially improving the quality of life for many people.

Not just on this forum, but beyond and the information you post here and on your blog leaks out and spreads.

Thanks

Jmr11820 profile image
Jmr11820

Thank you sir.

pleinairpainter profile image
pleinairpainter

Much appreciate your vigilance to keep us informed and to correct or amend misleading information.

treedown profile image
treedown

Thanks !

Kaliber profile image
Kaliber

Amen brother. Thanks for all your great work here. 👍👍👍

fluffyfur profile image
fluffyfur

Thank you so much TA.

kmack57 profile image
kmack57

Thanks TA I appreciate your input.

Doggedness profile image
Doggedness

Thank you!

ocman profile image
ocman

Thanks T_A, we always appreciate your input!

MiRob profile image
MiRob

Thank you T. Allen 🙏🏻

Nicnatno profile image
Nicnatno

TA, I'm on Xtandi now, so I hope to get a lot of years out of it.

Nick

tallguy2 profile image
tallguy2

Excellent post, thanks for sharing.

While I’m at it I encourage all of us to watch the Phase 2 trial at MD Anderson that involves two immunotherapy drugs. Very promising early results were reported during a webinar earlier this week. I don’t know if they recorded the session. Very technical but I came away feeling that when men fail the second-gen anti-androgens there is going to be a new option besides Jevtana.

Tall_Allen profile image
Tall_Allen in reply to tallguy2

Which 2 immunotherapy drugs?

tallguy2 profile image
tallguy2 in reply to Tall_Allen

Nivolumab and Ipilimumab. Study is being led by Dr. Padmanee Sharma.

tallguy2 profile image
tallguy2 in reply to tallguy2

This study is being conducted at many other sites in the USA and world-wide. All I can say is the results presented in preliminary form are quite amazing. Nobel Laureate Jim Allison was on this webinar.

Tall_Allen profile image
Tall_Allen in reply to tallguy2

Great to hear! I know it was reformulated from the first trial because side effects were too harsh, and it had minimal impact. I think they increased the nivo and decreased the ipi - sounds like they got it right this time.

tallguy2 profile image
tallguy2 in reply to Tall_Allen

I am looking for the recording and coming up blank. I came away with a lot of hope based on this webinar!

Blueslover profile image
Blueslover in reply to Tall_Allen

How is effectiveness assessed for this new CT?

I've just had Provenge and have been told there is no way to assess it's effect

Tall_Allen profile image
Tall_Allen in reply to Blueslover

They are looking for regression of tumors and fewer new tumors in those who take it vs those who don't. With immunotherapies, there may or may not be an effect on PSA. Effectiveness is assessed by randomized clinical trials, comparing groups of men who took it vs groups of men who took something else. It may or may not be obvious in any individual. For the individual, it may be impossible to predict what would have happened without the drugs.

Blueslover profile image
Blueslover in reply to Tall_Allen

Thanks.

So does Provenge have so little expected effect that MO's know that PSA or scans will not change?

Tall_Allen profile image
Tall_Allen in reply to Blueslover

It has a significant expected effect- those taking it live longer, whether PSA or scans change or not.

Blueslover profile image
Blueslover in reply to Tall_Allen

Thank you

Thanks for the additional information!

Bodysculpture profile image
Bodysculpture

Thank you Allen

You have helped me so much

Haniff profile image
Haniff

As always my heartfelt gratitude for going the distance and updating all of us, thanks TA ❤️

Haniff

kaptank profile image
kaptank

A year ago I confronted an onco I was considering changing to with this proposition to see what he made of it. It was pretty much TA's explanation along with a gentle hint that concluding that SCNC was caused by prior exposure to the new antiandrogens was a classic example of the ancient fallacy of post hoc ergo procter hoc (after the fact therefore because of the fact. He got the job.

leo2634 profile image
leo2634

Thank you TA. and Tall guy2 you have filled my day with hope.

curious-mind1 profile image
curious-mind1

I agree totally. My dad was on Zytiga for over five years, continuously, at full dose. Dr. Myers started him on the drug the second scans showed appearance of mets outside of the prostate bed. Last four years he was at a PSA of <0.006, Zytiga cleared all mets on the spinal cord and around the kidneys. Ultimately, he died of a brain anneryism and not his aggressive cancer, which was diagnosed as a Gleason 7 in 2000. These drugs certainly add years of cancer control when used earlier in the course of the disease!

Arthur

in reply to curious-mind1

Did you dad have any radiation or chemo to augment that ADT?

curious-mind1 profile image
curious-mind1 in reply to

No radiation or chemo. He did take Avodart and Lupron, per Myers' protocol at the time, as well as a low dose Estradiol patch to control side effects from the Lupron. Myers was prepared to augment the ADT with Xofigo or chemo, but Zytiga provided such good disease control, that it didn't become necessary.

My dad did have radiation therapy as his original treatment after diagnosis in 2000, along with a course of Lupron. He then went into a ten year remission from 2001 to 2011, before mets showed up in September 2014.

depotdoug profile image
depotdoug

Hope.

dorke profile image
dorke

Thank you TA for the time and dedication you put for this forum.

In general we were blessed in this forum to host several people like you that the word altruism is not strange for them.

davebliz profile image
davebliz

Thanks TA.

Cateydid profile image
Cateydid

I'm so grateful for the shared experiences on this forum, especially those supported by viable data. Thank you all!

tom67inMA profile image
tom67inMA

My MO was recently commenting that he has a couple other neuroendocrine cases. I mentioned the possible connection to abiraterone, and his reply was along the lines of "oh... wait... I forgot to give them abiraterone!" He has a great sense of humor.

dress2544 profile image
dress2544

Thanks T.A. for your valuable post

Dd7757 profile image
Dd7757

TA...is “ Simply The Best”.

Jawbreaker profile image
Jawbreaker

Thank you for comments , much appreciated

garyi profile image
garyi

This forum, and TA, never fail to inform and amaze me. Thank you for your caring devotion.

Schwah profile image
Schwah

I am so happy that you do not let the naysayers slow you down. Your work does not go unnoticed!

Schwah

MateoBeach profile image
MateoBeach

Thank you Tall_Allen. You are a valuable beacon for better treatment choices for all of us struggling with this terrifying disease on this and other sites. Please persist! Namo Namah

"The hormone therapies may only be selecting for the resistant cancer that survives their use." Isn't this the risk? So if Zytiga early use, selection of resistant cancer cells from beginning?

What do you think about this study:

sci-hub.tw/10.1038/s41467-0...

Tall_Allen profile image
Tall_Allen in reply to

That's just a pilot trial. When actually tested in full-scale RCTs (STAMPEDE and LATITUDE), CR does not come sooner with early use of Zytiga - in fact, the opposite is true - CR (failure-free survival) comes later when Zytiga is used earlier. The bottom line is patients live longer when Zytiga is used earlier.

LearnAll profile image
LearnAll in reply to

The issue of early and excessive use of ADT and early castration resistance is not dead yet.

In next few years, more and more clarity will be there about this topic because more research will reveal that prolonged, heavyduty ADT in fact leads to treatment resistant mutant cancer cells. At present, we just have to wait and see. No conclusion yet.

Tall_Allen profile image
Tall_Allen in reply to LearnAll

Throw away your crystal ball - it obviously is on the blink. It directly refutes what Aggarwal says - and I trust him a lot more than your intuitions.

LearnAll profile image
LearnAll in reply to Tall_Allen

No need to be unnecessarily angry. I am raising a possibility based on some research articles. You do not have to defend SOC so forcefully. Truth will defend itself. In the mean time, I have not/am not asking anyone to change their treatment plan. Just raising a doubt should not invite your rage. Everyone can have an opinion.

Tall_Allen profile image
Tall_Allen in reply to LearnAll

Everyone is entitled to their opinion, but there is only one version of the facts, which you persist in ignoring, sadly. Not angry. Mostly sad that you are in denial and trying to bring others into it.

LearnAll profile image
LearnAll in reply to Tall_Allen

When I started the post about possibility of Neuro endocrine differentiation, my aim was to create awareness about NE cell differentiation so members who are on Heavy duty ADT can keep close watch on biomarkers and scan findings to catch NE cells as early as possible.

I never knew that my post will create so much chaos and contraversy. That was unintended consequence.

I myself check LDH, Chromogranin A, Neuron enolase and osteolyic lesions on bones on regular intervals to monitor if any neuroendocrine component is starting.

People on this forum are intelligent and not gullible to change treatment because of opinions expressed by individual members. They will take into consideration all opinions and work with their doctors to get best treatment. That's what I believe.

Tall_Allen profile image
Tall_Allen in reply to LearnAll

Whatever you decide to do for yourself is your business. When you advocate it to others, pretending that facts back up your choices, that is a very destructive thing to do. STAMPEDE and LATITUDE results are not matters of opinion, they are facts. I could understand if you were ignorant of the facts, but I and others have repeatedly pointed them out to you, and yet you persist in presenting "alternative facts" (that's what Kellyanne Conway calls them - I call them out and out lies).

LearnAll profile image
LearnAll in reply to Tall_Allen

Stop your bullying language...I am not prescribing anything to anyone...You need to stop fighting and behaving like a bully. I presented the post based on some research articles which raised possibility of neuro-endocrine differentiation. And I am stating again that we do not know for sure if this possibility is true. But one thing is sure that number of neuro-endocrine cases are dramatically going up...You do not have monopoly on opinions. Now stop and mind your own business.

Tall_Allen profile image
Tall_Allen in reply to LearnAll

When you write posts that harm others, it is everyone's business. You heard from the horses mouth that you were misinterpreting his research - what more do you need? I think that everyone on here knows what your "opinions" are worth by now. You are free to express them, and I am free to point out that they are incorrect and misleading.

LearnAll profile image
LearnAll in reply to Tall_Allen

Not even one person has been harmed in any manner by my pointing out possibility of NE differentiation with heavy,prolonged ADT, In fact, it helps people as they can now be more vigilant about any change in cancer cells early on and also keep their doctors to watch more closely when patients are well informed about a possible risk.

I will certainly avail my right to express my opinion based on scientific information. My goal is not to win arguments with you...you can consider yourself a winner. Refrain from falsely accusing me that my posts are harming anyone. I do not ask anyone to try any substance or complementary treatments...I only present facts.

I have full confidence in member,s ability to sort out information and opinions and make informed decisions about their care. They are not babies who can get mislead.

Tall_Allen profile image
Tall_Allen in reply to LearnAll

How could you possibly know if any members here refrained from taking life-prolonging medications because of your misleading posts?

You went further than merely posting Aggarwal's study - you titled your post "WHEN CURE BECOMES WORSE THAN DISEASE..." and went on to say "to protect yourself from overzealous, unnecessary, very toxic treatments." You are harming patients. These are not facts- these are misleading statements. If you were merely ignorant - fine- now you know the truth directly from Aggarwal - just delete your thread, so no one else will be harmed.

ctarleton profile image
ctarleton in reply to LearnAll

Seems to me that there already are some findings/conclusions that have been verified and published. For example, in the LATITUDE trial, the use of ADT plus early Zytiga/Abiraterone delayed median progression-free survival from 14.8 months to 33.0 months. See Figure 1, Chart B in this report of trial results in the NEJM.

nejm.org/doi/full/10.1056/n...

The treatment effect in the added early abiraterone group was consistent across all the prespecified subgroups, which are typically indicative of "castration resistant" prostate cancer. See the Supplementary Figure S3 on page 8 of the Supplementary Appendix, showing the details of consistently demonstrated benefits across the entire range of the usual clinical measures which are indicative of advancing castration resistant disease, along with their 95% statistical confidence intervals.

nejm.org/doi/suppl/10.1056/...

If and when any delayed or intermittent or otherwise lower than recommended doses or regimens of basic or enhanced combination ADT treatments might be put to ethical, well-designed clinical trials, and they are completed, we can see those trial results when they are published in the peer-reviewed journals and at the major prostate cancer conferences.

My hat is off to all who participate in well-designed clinical trials that may advance our knowledge while protecting the participants. Some tentative hypotheses and ideas are harder to test with scientific rigor than others.

Another question: in the study LATITUDE you have a great advantage with early use of Zytiga, but they did not put in account the time of the use of Zytiga after ADT failure, did they?

That is: ADT + Zytiga vs ADT and ADT + Zytiga once ADT alone failed.

ctarleton profile image
ctarleton in reply to

Details about the patients and treatments and results in the LATITUDE study are here, including Overall Survival when, by the unanimous recommendation by the independent data and safety monitoring committee, the trial was unblinded and crossover was allowed for patients in the placebo group to receive abiraterone.

nejm.org/doi/full/10.1056/n...

You may also like...

Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show

overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC),...

How long did ADT work for you? How long did Xtandi/Zytiga work?

outcome. With emergence of newer hormone therapies I wonder how much longer until rising PSA or...

Early Randomized Clinical Trial suggests survival benefit to oligometastatic treatment using SBRT

that there MAY be a survival benefit to oligometastatic treatment using SBRT for various cancers....

High Gleason low PSA - quit ADT?

of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity...

Optimal chemohormonal sequencing for metastatic castration-resistant prostate cancer MAY be Taxotere->Zytiga->Jevtana->Xtandi

and hormonals like this seems to be optimal for metastatic castration-resistant prostate cancer...